Brazil’s Minimum Mandatory Coverage List Expands in 2023

Brazil’s collegiate directorate of the National Supplementary Health Agency (ANS) approved the inclusion of four medications to Brazil’s Minimum Mandatory Coverage List that must be mandatorily covered by health plans in the country. The four technologies will be offered to health plan users as of the publication of the update in the Normative Resolution that addresses the Minimum Mandatory Coverage List in the Union’s Official Gazette. The newly included medication are listed below.

Onasemnogeno abeparvoveque (Zolgensma®)

Zolgensma® considered the ‘world’s most expensive medicine,’ is the first advanced therapy to be included in the Minimum Mandatory Coverage List by health insurance providers and is indicated for the treatment of pediatric patients up to 6 months old with Spinal Muscular Atrophy (SMA) type I who have been out of the invasive mechanical ventilation for more than 16 hours a day.

Dupilumabe

Dupilumabe is used for the treatment of patients with severe atopic dermatitis with an indication for systemic treatment and who present failure, intolerance, or contraindication to cyclosporine

Zanubrutinibe

Used in the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

Komosozumabe

The immunobiological medication Romosozumab, is indicated for the treatment of women with osteoporosis in the postmenopausal period, from the age of 70 onwards, and who have failed in the treatment with other medication.

 

Sciath, Asinta’s employee benefits Partner in Brazil, provided this information about Brazil’s minimum mandatory coverage list.